Klaus A. Dugi

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

Baptist Gallwitz, Julio Rosenstock, T. Rauch et al. · The Lancet · 2012 · 340 citations

Medicine, Pharmacology, Pharmacotherapy +12

Effect of linagliptin monotherapy on glycaemic control and markers of <i>β</i> ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

Stefano Del Prato, Anthony Barnett, Holger Huisman et al. · Diabetes Obesity and Metabolism · 2010 · 298 citations

Medicine, Pharmacology, Pharmacotherapy +17

Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

Marja‐Riitta Taskinen, Julio Rosenstock, Ilkka Tamminen et al. · Diabetes Obesity and Metabolism · 2010 · 293 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study¹

D. R. Owens, Ros Swallow, Klaus A. Dugi et al. · Diabetic Medicine · 2011 · 213 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

Ramón Gomis, Rosa-Maria Espadero, Russell Jones et al. · Diabetes Obesity and Metabolism · 2011 · 177 citations

Medicine, Pharmacology, Pharmacotherapy +16